Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies

European Journal of Cancer

Volumn 49, Issue 14, 2013, Pages 2968-2971

  Robert, Caroline ^a   Soria, Jean Charles ^a   Eggermont, Alexander M M ^a  

^a Cancer Institute Gustave Roussy   (France)

Author keywords

Checkpoint inhibitors; Drug development; Immunotherapy; PD 1 PD L1

Indexed keywords

ANTINEOPLASTIC AGENT; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IPILIMUMAB; LAMBROLIZUMAB; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1 RECEPTOR MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR MONOCLONAL ANTIBODY; TICILIMUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG CANCER; MELANOMA; MELANOMA CELL; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

CHECKPOINT INHIBITORS; DRUG DEVELOPMENT; IMMUNOTHERAPY; PD-1/PD-L1;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; TREATMENT OUTCOME;

EID: 84883050318     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.07.001     Document Type: Article

References (25)

1. D. Pardoll The blockade of immune checkpoints in immunotherapy Nat Rev Cancer 12 4 2012 252 264
2. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 5256 1996 1734 1736
3. A. Ribas Clinical development of the anti-CTLA-4 antibody tremelimumab Semin Oncol 37 2010 450 454
4. J.S. Weber, S. O'Day, and W. Urba Phase I/II study of ipilimumab for patients with metastatic melanoma J Clin Oncol 26 2008 5950 5956
5. A. Ribas, R. Kefford, and M.A. Marshall Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol 31 2013 [epub ahead of print]
6. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
7. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
8. P. Attia, G.Q. Phan, and A.V. Maker Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4 J Clin Oncol 23 2005 6043 6053
9. A.M.M. Eggermont, and C. Robert New drugs in melanoma: it's a whole new world Eur J Cancer 47 14 2011 2150 2157
10. S. Amarnath, C.W. Mangus, and J.C. Wang The PDL1-PD1 axis converts human TH1 cells into regulatory T cells Sci Transl Med 3 111 2011 111ra120
11. L.J. Hatam, J.A. Devoti, and D.W. Rosenthal Immune suppression in premalignant respiratory papillomas: enriched functional CD4 + Foxp3 + regulatory T cells and PD-1/PD-L1/L2 expression Clin Cancer Res 18 7 2012 1925 1935
12. S.L. Topalian, F.S. Hodi, and J.R. Brahmer Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
13. M. Sznol, H.M. Kluger, and F.S. Hodi Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) J Clin Oncol 31 Suppl. 2013 [abstr. CRA9006]
14. O. Hamid, C. Robert, and A. Daud Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma N Engl J Med 2013 [epub ahead of print]
15. J.R. Brahmer, S.S. Tykodi, and L.Q.M. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
16. J.D. Wolchok, H. Kluger, and M.K. Callahan Nivolumab plus Ipilimumab in advanced melanoma N Engl J Med 2013 [epub ahead of print]
17. E.J. Lipson, W.H. Sharfman, and C.G. Drake Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody Clin Cancer Res 19 2 2013 462 468
18. O. Hamid, J. Sosman, and J.D. Lawrence Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic melanoma J Clin Oncol 31 Suppl. 2013 [abstr. 9010]
19. J.R. Brahmer, L. Horn, and S.J. Antonia Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) J Clin Oncol 31 Suppl. 2013 [abstr. 8030]
20. D. Spigel, S.N. Gettinger, and L. Horn Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 31 Suppl. 2013 [abstr. 8008]
21. J. Powderly, H. Koeppen, and F.S. Hodi Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study J Clin Oncol 31 Suppl. 2013 [abstr. 3001]
22. D. Cho, J.A. Sosman, and K. Sznol Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (RCC) J Clin Oncol 31 Suppl. 2013 [abstr. 4505]
23. C.G. Drake, D.F. McDermott, and M. Sznol Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up J Clin Oncol 31 Suppl. 2013 [abstr. 4514]
24. F.S. Hodi, S.J. Lee, and D.F. McDermott Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 J Clin Oncol 31 Suppl. 2013 [abstr. CRA9007]
25. A.M.M. Eggermont, G. Kroemer, and L. Zitvogel Immunotherapy and the concept of clinical cure Eur J Cancer 49 2013 2965 2967